Edwards’ TAVR results hurt by pandemic aftereffects and competition in Q2

Growth of Edwards Lifesciences’ key transcatheter aortic valve replacement (TAVR) franchise slowed sequentially in the second quarter as the company continued to contend with aftereffects of the pandemic and competitive pressures in Japan.